CORONA REMEDIES
Back to Cashflow Statement
|
CORONA REMEDIES Last 5 Year Cash Flow from Operating Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Cash Flow from Operating Activities | ₹229 Cr | ₹190 Cr | ₹157 Cr | ₹103 Cr |
What is the latest Cash Flow from Operating Activities ratio of CORONA REMEDIES ?
| Year | Cash Flow from Operating Activities |
|---|---|
| Mar2026 | ₹229 Cr |
| Mar2025 | ₹190 Cr |
| Mar2024 | ₹157 Cr |
| Mar2023 | ₹103 Cr |
How is Cash Flow from Operating Activities of CORONA REMEDIES Trending?
| Years | Cash Flow from Operating Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹229 Cr | 20.47 | |
| Mar2025 | ₹190 Cr | 21.52 | |
| Mar2024 | ₹157 Cr | 52.64 | |
| Mar2023 | ₹103 Cr | - | |
Compare Cash Flow from Operating Activities of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹13,925.1 Cr | -3.7% | 13.8% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹448,688.0 Cr | -1.4% | 6.3% | 7.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹295,080.0 Cr | -1.8% | 20.6% | 70.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,677.0 Cr | -1.9% | 2.4% | 22.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹115,852.0 Cr | 0.8% | 12.6% | 12.3% | Stock Analytics | |
| CIPLA | ₹111,731.0 Cr | -2.4% | 4.4% | -8.3% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | -3.7% |
13.8% |
|
| SENSEX | 1.8% |
11.1% |
-1.6% |
You may also like the below Video Courses